HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICCVAM

This article was originally published in The Rose Sheet

Executive Summary

Federal agencies' responses to recommendations on non-animal test methods for assessing allergic contact dermatitis hazard potential of chemicals is now available, reports the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods. Two test methods recommended to the agencies by ICCVAM were the murine local lymph node assay (LLNA), which uses 20% fewer animals than the original protocol recommended in 1999, and the reduced murine local lymph node assay (rLLNA), which can reduce animal use by 40% compared with the standard LLNA. ICCVAM gave agencies - including FDA, the EPA and the Consumer Product Safety Commission - 180 days to respond to its favorable recommendation for the tests, which comes after consideration of a peer review panel report, public comments and feedback from its Scientific Advisory Committee on Alternative Toxicological Methods (1"The Rose Sheet" Oct. 19, 2009, In Brief)

You may also be interested in...



ICCVAM vouches for rLLNA

The Food and Drug Administration, the Environmental Protection Agency, the Consumer Product Safety Commission and other federal agencies have 180 days to respond to favorable recommendation for the reduced murine local lymph node assay, submitted by the Interagency Coordinating Committee on the Validation of Alternative Methods. Used to assess chemicals' potential to cause allergic contact dermatitis, the rLLNA "is sufficient to distinguish between skin sensitizers and non-sensitizers for testing situations that do not require dose-response information," ICCVAM says. Committee notes that the alternative strategy reduces animal use by 40 percent for each test compared with traditional multi-dose LLNA. ICCVAM's recommendation comes after consideration of a peer review panel report, public comments and feedback from its Scientific Advisory Committee on Alternative Toxicological Methods. The group also has turned over to its member agencies LLNA test method standards for "more efficiently evaluat[ing] the validity of modified test methods that are similar to the traditional LLNA.

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

UsernamePublicRestriction

Register

RS016928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel